...
首页> 外文期刊>The Journal of dermatological treatment >A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole
【24h】

A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole

机译:荟萃分析比较了特比萘芬与伊曲康唑成功治疗后趾甲甲癣的长期复发

获取原文
获取原文并翻译 | 示例
           

摘要

As the most frequently used systemic antifungal agents for onychomycosis, terbinafine and itraconazole have both proved to have the conditions of recurrence in various degrees during follow-up period after end of therapy; very little is known about their comparative recurrences after long-term follow-up. We conducted a meta-analysis of available trials to compare the long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. Meta-analysis was performed by the Review Manager version 5.0.25. Risk ratio and 95% confidence intervals were calculated by the fixed effect model. Five trials and total 251 eligible patients were included in this meta-analysis. The combined risk ratio of the meta-analysis comparing terbinafine with itraconazole for mycological recurrence rate was 0.44 (95% CI 0.29-0.66), which suggests that itraconazole therapy is more likely to produce mycological recurrence compared with terbinafine therapy.
机译:作为用于灰指甲病的最常用的全身性抗真菌药,特比萘芬和伊曲康唑均已证明在治疗结束后的随访期内均有不同程度的复发。对其长期随访后的相对复发了解甚少。我们对现有试验进行了荟萃分析,以比较特比萘芬与伊曲康唑成功治疗后趾甲甲癣的长期复发情况。 Meta分析由Review Manager 5.0.25版执行。通过固定效应模型计算风险比和95%置信区间。这项荟萃分析包括五项试验和总共251名合格患者。特比萘芬与伊曲康唑比较的荟萃分析的合计风险比为0.44(95%CI 0.29-0.66),这表明与特比萘芬相比,伊曲康唑治疗更容易产生真菌学复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号